Immunology Investor Event

sanofi Amlitelimab, an anti-OX40L, rebalances inflammation without immunosuppressive cell depletion in early studies. Virus Allergens Epithelial Injury OX40L blockade with advantages to OX40 depletion OX40L OX40 Blocker Depleter TSLP, IL-33, IL-25 Limited expression at sites of inflammation ✓ APC Preserves Teff, Tmem cells ✓ amlitelimab OX40L ↑ Preserves and activates Treg × OX40 eff mem Avoids cytokine release (fever, chills) Treg The information on this slide is for purposes of illustrating Amlitelimab's differentiated MoA. No conclusions should be drawn regarding the clinical efficacy of Amlitelimab alone or in comparison to any other treatment. No head to head studies comparing the referenced MoAs have been conducted. Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. Need to be confirmed in Ph3 trials. 31 Immunology Investor Event

View entire presentation